Top Treatment Takeaways from the World Conference on Lung Cancer

Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s work as well as learning about the latest treatment updates.

Immunotherapy

Immunotherapy drugs help a person’s own immune system fight back against their cancer.

CheckMate 227

For people with non-small cell lung cancer (NSCLC) without a targetable mutation

A five-year analysis of the first-line combination of nivolumab (Opdivo) + ipilimumab (Yervoy) showed a positive long-term response for people with NSCLC without a targetable mutation compared to chemotherapy alone. It found better disease control and survival, regardless of PD-L1 (a protein that drugs can target) testing results.

Keynote-189

For people with NSCLC and a PD-L1 less than 1%

This study found that pembrolizumab (Keytruda) combined with chemotherapy is a safe and effective choice for people with NSCLC and a PD-L1 less than 1% without a targeted therapy option. Over half of study participants are still alive three years after completing therapy.

Antibody-Drug Conjugates (ADCs)

ADCs are a newer type of therapy for cancer. These medicines have an antibody which will identify part of the cancer cell to attach to exclusively, meaning the drugs are designed to have fewer off-target side-effects and greater specific impact. Once attached, they release a high dose of cancer-killing medicine directly into the tumor.

EVOKE-02

For people with NSCLC receiving first-line treatment

This phase II (2) study showed that a combination of TRODELVY (sacituzumab-govitecan) plus pembrolizumab (Keytruda) is safe, tolerable, and effective for people with NSCLC as a first treatment option.

Herthena Lung-01

For people with EGFR+ NSCLC

This study confirmed that someone with EGFR+ NSCLC who has progressed on targeted therapy and chemotherapy can receive a significant and sustainable benefit from the ADC medication patritumab-deruxtecan (HER3-DXd).

Targeted Therapy

Targeted therapy can be given to people whose cancer is caused by a specific mutation that the targeted therapy is designed to block.

FLAURA-2

For people with advanced EGFR+ NSCLC

Updated data from this study found that osimertinib (Tagrisso) combined with platinum doublet chemotherapy produced a stronger impact than osimertinib (Tagrisso) alone in the first-line setting for advanced EGFR+ NSCLC.

CHRYSALIS-2

For people with EGFR+ lung cancer who have progressed on other therapies

Results found that a combination of EGFR/MET targeted antibody called amivantamab (Rybrevant) combined with the EGFR targeted therapy Lazertinib and chemotherapy work well together for people who have progressed on drugs like osimertinib (Tagrisso). Over 80% of people in the study were still alive one year later.

ZENITH20

For people with NSCLC and a HER2 Exon20 mutation

Results showed that taking poziotinib may now present a new treatment option after experiencing progression on two or more other therapies.

Phase 3 Study

For people with NSCLC and a MET Exon 14 skipping mutation

A phase 3 study from China looking at the medication savolitinib found that this drug produced a significant, durable response for those with NSCLC and a MET exon 14 skipping mutation who are new to treatment. Studies for this drug are also ongoing in the U.S.

KontRASt-01

For people who have progressed on prior therapy with a KRAS G12C mutation

The study is looking at a new therapeutic combination of a novel KRAS inhibitor combined with another medicine known as a SHP2 inhibitor for people who have progressed on prior therapy with a KRAS G12C mutation. The phase 1 analysis found meaningful response and duration and is encouraging for people who may have progressed on prior KRAS inhibitors.

CodeBreaK-101

For people with a KRAS G12C mutation

Use of sotorasib (Lumakras) along with platinum doublet chemotherapy for KRAS G12 C positive people in the first/second line was analyzed in CodeBreaK-101 and was found to be promising. Further studies looking at the long-term effectiveness continue.

Trident-1

For people with ROS1+ NSCLC

Updated data confirmed repotrectinib produced meaningful and durable responses in people with ROS1+ NSCLC who were new to treatment or had been pre-treated, as well as people whose lung cancer had spread to the brain.

Therapeutic Advances in SCLC

CeLEBrATE

For people with extensive stage small cell lung cancer

This Italian study found evidence supporting a new potential first line therapy combination for ES-SCLC (extensive stage small cell lung cancer). Their results show that the VEGF inhibitor bevacizumab (Avastin) when given with atezolizumab (Tecentriq), platinum-based chemo, and etoposide is a safe and effective regimen warranting further study.

Rationale-312